文献速递乳腺癌

MINDACT试验中未接受任何辅助全身治疗的I期ER+/HER2-乳腺癌患者的结局

Outcome without any adjuvant systemic treatment in stage I ER+/HER2- breast cancer patients included in the MINDACT trial.
PubMed 文献 · Ann Oncol · 2021-12-01

该研究基于EORTC 10041/BIG 3-04 MINDACT试验,将509例未接受辅助全身治疗(AST)的雌激素受体阳性、HER2阴性、淋巴结阴性、肿瘤≤2 cm的I期乳腺癌患者,按倾向性评分和年龄、基因组风险(70基因签名)、分级精确匹配,1:1匹配至509例仅接受辅助内分泌治疗(ET)的患者。中位随访8年时,两组无远处转移间期(DMFI)和总生存(OS)无统计学显著差异,但未接受AST组局部区域复发(LRR)和对侧乳腺癌(CBC)累积发生率数值上高于仅接受ET组,且ET组总体乳腺癌事件更少。

要点

  • 8年DMFI:未接受AST组94.8% vs 仅ET组97.3%,绝对差2.5%,HR 0.56(95%CI 0.30-1.03),未达统计学显著。
  • 8年OS:未接受AST组95.4% vs 仅ET组95.6%,绝对差0.2%,HR 0.86(95%CI 0.53-1.41),无统计学显著差异。
  • 8年LRR累积发生率:未接受AST组4.7% vs 仅ET组1.4%;CBC:未接受AST组4.6% vs 仅ET组1.5%。

核心结论

  • 在I期低风险乳腺癌患者中,内分泌治疗对无远处转移间期的影响有限,但随访8年后接受内分泌治疗的患者总体乳腺癌事件显著更少。
  • 应与所有患者讨论内分泌治疗的获益与副作用,即使远处转移风险极低的患者也是如此。

研究设计与样本

  • 基于EORTC 10041/BIG 3-04 MINDACT试验的事后分析。
  • 纳入雌激素受体阳性、HER2阴性、淋巴结阴性、肿瘤≤2 cm且未接受任何辅助全身治疗的患者509例。
  • 采用倾向性评分匹配及年龄、基因组风险(70基因签名)、分级的精确匹配,1:1匹配至仅接受辅助内分泌治疗的患者509例。
  • 采用Kaplan-Meier法评估无远处转移间期和总生存,Cox回归计算风险比,竞争风险分析评估局部区域复发和对侧乳腺癌的累积发生率。

主要发现

  • 8年无远处转移间期率:未接受辅助全身治疗组94.8%(95%CI 92.7%-96.9%) vs 仅内分泌治疗组97.3%(95%CI 95.8%-98.8%),绝对差2.5%,HR 0.56(95%CI 0.30-1.03)。
  • 8年总生存率:未接受辅助全身治疗组95.4%(95%CI 93.5%-97.4%) vs 仅内分泌治疗组95.6%(95%CI 93.8%-97.5%),绝对差0.2%,HR 0.86(95%CI 0.53-1.41),无统计学显著差异。
  • 局部区域复发累积发生率:未接受辅助全身治疗组4.7%(95%CI 3.0%-7.0%) vs 仅内分泌治疗组1.4%(95%CI 0.6%-2.9%)。
  • 对侧乳腺癌累积发生率:未接受辅助全身治疗组4.6%(95%CI 2.9%-6.9%) vs 仅内分泌治疗组1.5%(95%CI 0.6%-3.1%)。

临床怎么用

  • 作者认为,应与所有I期低风险乳腺癌患者讨论内分泌治疗的获益与副作用,即使远处转移风险极低的患者也是如此。

局限性

  • 原文报告随访时间相对较短,为8年。
  • 该分析为事后分析。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Adjuvant systemic treatments (AST) reduce mortality, but have associated short- and long-term toxicities. Careful selection of patients likely to benefit from AST is needed. We evaluated outcome of low-risk breast cancer patients of the EORTC 10041/BIG 3-04 MINDACT trial who received no AST. PATIENTS AND METHODS: Patients with estrogen receptor-positive, HER2-negative, lymph node-negative tumors ≤2 cm who received no AST were matched 1 : 1 to patients with similar tumor characteristics treated with adjuvant endocrine therapy (ET), using propensity score matching and exact matching on age, genomic risk (70-gene signature) and grade. In a post hoc analysis, distant metastasis-free interval (DMFI) and overall survival (OS) were assessed by Kaplan-Meier analysis and hazard ratios (HR) by Cox regression. Cumulative incidences of locoregional recurrence (LRR) and contralateral breast cancer (CBC) were assessed with competing risk analyses. RESULTS: At 8 years, DMFI rates were 94.8% [95% confidence interval (CI) 92.7% to 96.9%] in 509 patients receiving no AST, and 97.3% (95% CI 95.8% to 98.8%) in 509 matched patients who received only ET [absolute difference: 2.5%, HR 0.56 (95% CI 0.30-1.03)]. No statistically significant difference was seen in 8-year OS rates, 95.4% (95% CI 93.5% to 97.4%) in patients receiving no AST and 95.6% (95% CI 93.8% to 97.5%) in patients receiving only ET [absolute difference: 0.2%, HR 0.86 (95% CI 0.53-1.41)]. Cumulative incidence rates of LRR and CBC were 4.7% (95% CI 3.0% to 7.0%) and 4.6% (95% CI 2.9% to 6.9%) in patients receiving no AST versus 1.4% (95% CI 0.6% to 2.9%) and 1.5% (95% CI 0.6% to 3.1%) in patients receiving only ET. CONCLUSIONS: In patients with stage I low-risk breast cancer, the effect of ET on DMFI was limited, but overall significantly fewer breast cancer events were observed in patients who received ET, after the relatively short follow-up of 8 years. These benefits and side-effects of ET should be discussed with all patients, even those at a very low risk of distant metastasis.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Lopes Cardozo JMN, Byng D, Drukker CA, et al. Outcome without any adjuvant systemic treatment in stage I ER+/HER2- breast cancer patients included in the MINDACT trial. Ann Oncol. 2021. PMID: 34861376. doi:10.1016/j.annonc.2021.11.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。